PARP1 and ovarian cancer: Literature proposes several meta-analyses which evaluate the efficacy of PARP inhibitors both as maintenance therapy after first line chemotherapy (8) as maintenance therapy in platinum-sensitive recurrence (10) confirming the recommendation for the use of PARP inhibitors in patients with ovarian cancer, albeit with different levels of benefit based on the HRD phenotype.